Igor T. Gavrilovic

TL;DR: Brain metastases are the most common tumors of the central nervous system (CNS), but cancer databases are often incomplete leading to underestimation of the incidence of even symptomatic brain metastases, which may lead to the development of more efficient therapies to combat brain tumor growth.

TL;DR: Long-term follow-up of the initial cohort confirms the observation of excellent overall survival, particularly for those patients younger than age 60 at diagnosis, and it appears to be reasonable to defer whole brain radiotherapy in an effort to minimize treatment-related neurotoxicity.

TL;DR: This high-dose chemotherapy with autologous stem-cell transplant with HDC-ASCT was associated with excellent disease control and survival, an acceptable toxicity profile, and no evidence of neurotoxicity thus far.

TL;DR: Sunitinib is active in recurrent atypical/malignant meningioma patients and should be performed in a randomized trial.

TL;DR: Both dose-dense and metronomic temozolomide regimens were well tolerated with modest toxicity and the dose- dense regimen appears promising, with 1-year survival of 80%.